NDA 022406 · Janssen Pharms
Xarelto
Rivaroxaban · Oral · Factor Xa Inhibitor
NovelLast checked: Nov 20, 2026Latest source record: Mar 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2011
Jul 1, 2011
Approved uses
7
Original approval plus efficacy supplements
Registered trials
419
129 Phase 3, 75 recruiting
FAERS reports
208,599
174,869 serious, 27,259 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: (A) PREMATURE DISCONTINUATION OF XARELTO INCREASES THE RISK OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA A. Premature discontinuation of XARELTO increases the risk of thrombotic events Premature discontinuation of any oral anticoagulant, including XARELTO, increases the risk of thrombotic events. If anticoagulation with XARELTO is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant [see Dosage and Administration (2.3 , 2.4) , Warnings and Precautions (5.1) , and Clinical Studies (14.1) ] . B. Spinal/epidural hematoma Epidural or spinal hematomas have occurred in patients treated with XARELTO who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal...
What it is approved for
From the label in effect Sep 10, 2026.
XARELTO is a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) for treatment of deep vein thrombosis (DVT) ( 1.2 ) for treatment of pulmonary embolism (PE) ( 1.3 ) for reduction in the risk of recurrence of DVT or PE ( 1.4 ) for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation XARELTO is indicated to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. There are limited data on the relative effectiveness of XARELTO and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well-controlled [see Clinical Studies (14.1) ]. 1.2 Treatment of Deep Vein Thrombosis XARELTO is indicated for the treatment of deep vein thrombosis (DVT). 1.3 Treatment of Pulmonary Embolism XARELTO is indicated for the treatment of pulmonary embolism (PE). 1.4 Reduction in the Risk of Recurrence of Deep Vein Thrombosis and/or Pulmonary Embolism XARELTO is...
Mechanism: XARELTO is a selective inhibitor of FXa. It does not require a cofactor (such as Anti-thrombin III) for activity. Rivaroxaban inhibits free FXa and prothrombinase activity. Rivaroxaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, rivaroxaban decreases thrombin generation.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 11, 2019 Supplement 33 · Efficacy LabelLetter
- Oct 27, 2017 Supplement 24 · Efficacy · priority review LabelLetter
- Mar 1, 2013 Supplement 4 · Efficacy LetterLabel
- Nov 2, 2012 Supplement 3 · Efficacy · priority review LabelLetter
- Nov 2, 2012 Supplement 1 · Efficacy · priority review LabelLetter
- Nov 2, 2012 Supplement 2 · Efficacy · priority review LetterLabel
- Jul 1, 2011 Original approval · Type 1 - New Molecular Entity NovelLetterLabelReview
4 products under this application
- XARELTO · RIVAROXABAN 20MG · TABLET, ORAL · Prescription · TE AB
- XARELTO · RIVAROXABAN 10MG · TABLET, ORAL · Prescription · TE AB
- XARELTO · RIVAROXABAN 2.5MG · TABLET, ORAL · Prescription · TE AB
- XARELTO · RIVAROXABAN 15MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Rivaroxaban" as an intervention, any sponsor and status, largest first.
- Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery DiseasePivotal-lookingCompleted
BayerBayer (BAYRY)
NCT01776424 · 27,395 participants · Start Feb 28, 2013 · Primary completion Jul 21, 2017
Drug: Rivaroxaban (Xarelto, BAY59-7939); Rivaroxaban (Xarelto, BAY59-7939) and 5 more · For: Prevention & Control
Sites: Birmingham, Alabama; Mobile, Alabama; Anaheim, California · 565 sites in all
- Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee ReplacementPivotal-lookingCompleted
Dartmouth-Hitchcock Medical CenterAcademic, hospital or other
NCT02810704 · 18,883 participants · Start Dec 2016 · Primary completion Sep 2025
Drug: Enteric Coated Aspirin; Warfarin and 1 more · For: Pulmonary Embolism; Venous Thrombosis
Sites: Scottsdale, Arizona; Little Rock, Arkansas; Los Angeles, California · 32 sites in all
- An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary SyndromePivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00809965 · 15,526 participants · Start Nov 2008 · Primary completion Sep 2011
Drug: Rivaroxaban 2.5 mg; Rivaroxaban 5 mg and 2 more · For: Acute Coronary Syndrome; Myocardial Infarction; Myocardial Ischemia and 1 more
Sites: Birmingham, Alabama; Geneva, Alabama; Mobile, Alabama · 556 sites in all
- An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial FibrillationPivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00403767 · 14,269 participants · Start Dec 2006 · Primary completion Sep 2010
Drug: Rivaroxaban; Warfarin and 2 more · For: Atrial Fibrillation; Stroke; Embolism
Sites: Birmingham, Alabama; Dothan, Alabama; Geneva, Alabama · 932 sites in all
- A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge PatientsPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT02111564 · 12,024 participants · Start Jan 7, 2014 · Primary completion Mar 6, 2018
Drug: Rivaroxaban, 10 mg; Rivaroxaban, 7.5 mg and 1 more · For: Heart Failure; Respiratory Insufficiency; Stroke Acute and 2 more
Sites: Birmingham, Alabama; Mobile, Alabama; Sheffield, Alabama · 593 sites in all
- The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial FibrillationPivotal-lookingActive, not recruiting
Herlev and Gentofte HospitalAcademic, hospital or other
NCT03129490 · 11,000 participants (planned) · Start Apr 1, 2023 · Primary completion Oct 30, 2027
Drug: Dabigatran Etexilate Oral Capsule; Rivaroxaban Oral Tablet and 2 more · For: Atrial Fibrillation; Atrial Flutter
Sites: Aalborg, Denmark; Aarhus, Denmark; Ballerup Municipality, Denmark · 38 sites in all
- Thromboprophylaxis in Lower Limb ImmobilisationPivotal-lookingRecruiting
Queen Mary University of LondonAcademic, hospital or other
NCT06370273 · 10,044 participants (planned) · Start Nov 12, 2024 · Primary completion Aug 31, 2028
Drug: Rivaroxaban; Apixaban and 4 more · For: Thrombosis; Injury Leg
Sites: Carshalton, United Kingdom; Hull, United Kingdom; London, United Kingdom · 5 sites in all
- Comparing the Safety and Efficacy of Apixaban and RivaroxabanPivotal-lookingRecruiting
VA Office of Research and DevelopmentFederal agency
NCT06953726 · 10,000 participants (planned) · Start Jun 1, 2026 · Primary completion Oct 4, 2032
Drug: Apixaban; Rivaroxaban · For: Atrial Fibrillation
Sites: West Los Angeles, California; Miami, Florida; Boston, Massachusetts · 9 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- gastrointestinal haemorrhage21,673
- off label use8,056
- haemorrhage7,819
- dyspnoea7,421
- epistaxis6,806
- fatigue6,801
- death6,190
- fall6,184
- pulmonary embolism6,046
- drug ineffective6,005
- diarrhoea5,790
- anaemia5,772
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 4 |
| 2008 | 3 |
| 2009 | 52 |
| 2010 | 55 |
| 2011 | 503 |
| 2012 | 3,861 |
| 2013 | 7,368 |
| 2014 | 9,409 |
| 2015 | 27,674 |
| 2016 | 29,714 |
| 2017 | 22,442 |
| 2018 | 21,010 |
| 2019 | 21,502 |
| 2020 | 14,671 |
| 2021 | 10,008 |
| 2022 | 10,492 |
| 2023 | 9,332 |
| 2024 | 8,319 |
| 2025 | 7,035 |
| 2026 | 5,145 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Xarelto (Rivaroxaban)
2024 spending
$6.23B
Beneficiaries
1,321,019
6,660,246 claims
Per beneficiary
$4,718
$17.68 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $4,701,314,805 |
| 2021 | $5,225,547,772 |
| 2022 | $5,772,682,548 |
| 2023 | $6,309,246,823 |
| 2024 | $6,232,231,840 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism.
Castellucci LA, Chen VM, Kovacs MJ, et al. · N Engl J Med 2026 · Clinical Trial, Phase IV, Comparative Study
- Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome.
Pengo V, Denas G, Zoppellaro G, et al. · Blood 2018 · Clinical Trial, Phase III, Multicenter Study
- Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation.
Verma A, Birnie DH, Jiang C, et al. · N Engl J Med 2026 · Clinical Trial, Phase IV, Equivalence Trial
- Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
Patel MR, Mahaffey KW, Garg J, et al. · N Engl J Med 2011 · Comparative Study, Multicenter Study
- Rivaroxaban in Peripheral Artery Disease after Revascularization.
Bonaca MP, Bauersachs RM, Anand SS, et al. · N Engl J Med 2020 · Multicenter Study, Randomized Controlled Trial
- Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial.
Male C, Lensing AWA, Palumbo JS, et al. · Lancet Haematol 2020 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.